188 related articles for article (PubMed ID: 16474813)
21. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
[TBL] [Abstract][Full Text] [Related]
22. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
Sternberg CN
BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
[No Abstract] [Full Text] [Related]
23. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
24. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
Urologiia; 2001; (4):26-9. PubMed ID: 11569230
[TBL] [Abstract][Full Text] [Related]
25. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
[TBL] [Abstract][Full Text] [Related]
26. Bicalutamide-associated fulminant hepatotoxicity.
O'Bryant CL; Flaig TW; Utz KJ
Pharmacotherapy; 2008 Aug; 28(8):1071-5. PubMed ID: 18657023
[TBL] [Abstract][Full Text] [Related]
27. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
28. Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model.
Yamauchi A; Kawai K; Tsukamoto S; Ideyama Y; Shirai T; Akaza H
J Urol; 2006 Jan; 175(1):348-52. PubMed ID: 16406940
[TBL] [Abstract][Full Text] [Related]
29. [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].
Yoshida T; Nishimura K; Uemura M; Nakagawa K; Harada Y; Kanno N; Miyoshi S; Kawano K
Hinyokika Kiyo; 2006 Nov; 52(11):891-4. PubMed ID: 17176877
[TBL] [Abstract][Full Text] [Related]
30. Treatment of bicalutamide-induced breast events.
Sieber PR
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
[TBL] [Abstract][Full Text] [Related]
31. [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].
Bolla M; Maingon P; Fourneret P; Artignan X; Descotes JL
Cancer Radiother; 2005 Nov; 9(6-7):394-8. PubMed ID: 16226044
[TBL] [Abstract][Full Text] [Related]
32. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
[TBL] [Abstract][Full Text] [Related]
34. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer.
Van Poppel H; Tyrrell CJ; Haustermans K; Cangh PV; Keuppens F; Colombeau P; Morris T; Garside L
Eur Urol; 2005 May; 47(5):587-92. PubMed ID: 15826748
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Kurko B
Urology; 2006 Jul; 68(1):116-20. PubMed ID: 16844453
[TBL] [Abstract][Full Text] [Related]
37. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
Takeshita H; Kawakami S; Fukui I
Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
[No Abstract] [Full Text] [Related]
38. Treatment of clinically organ confined prostate cancer.
McLeod DG
Scand J Urol Nephrol Suppl; 1999; 203():35-9. PubMed ID: 10636568
[No Abstract] [Full Text] [Related]
39. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
[TBL] [Abstract][Full Text] [Related]
40. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
